91 related articles for article (PubMed ID: 14552720)
1. [Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive].
Jin RH; Lang ZW; Yao GB; Guo XH
Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):555-7. PubMed ID: 14552720
[TBL] [Abstract][Full Text] [Related]
2. [A study on the clinical and pathological efficacy of lamivudine in the treatment of chronic hepatitis B].
Yang C; Xiao YH; Guan XQ; Yuan Z
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):364-7. PubMed ID: 15225436
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
4. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
Kuloglu Z; Krsaçloglu CT; Kansu A; Erden E; Girgin N
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):564-8. PubMed ID: 18030234
[TBL] [Abstract][Full Text] [Related]
5. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
6. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
7. Liver disease-significant improvement with lamivudine.
Leung N
J Med Virol; 2000 Jul; 61(3):380-5. PubMed ID: 10861650
[TBL] [Abstract][Full Text] [Related]
8. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
10. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.
Nikolaidis N; Vassiliadis T; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
Clin Transplant; 2005 Jun; 19(3):321-6. PubMed ID: 15877792
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B with lamivudine.
Khokhar N; Gill ML; Alam AY
J Coll Physicians Surg Pak; 2005 Feb; 15(2):78-80. PubMed ID: 15730830
[TBL] [Abstract][Full Text] [Related]
12. Histological outcome during long-term lamivudine therapy.
Dienstag JL; Goldin RD; Heathcote EJ; Hann HW; Woessner M; Stephenson SL; Gardner S; Gray DF; Schiff ER
Gastroenterology; 2003 Jan; 124(1):105-17. PubMed ID: 12512035
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
15. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection.
Suzuki Y; Kumada H; Ikeda K; Chayama K; Arase Y; Saitoh S; Tsubota A; Kobayashi M; Koike M; Ogawa N; Tanikawa K
J Hepatol; 1999 May; 30(5):743-8. PubMed ID: 10365796
[TBL] [Abstract][Full Text] [Related]
16. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
17. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
20. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
